Heartflow, Inc. Files 8-K on Financials and Reg FD

TL;DR

Heartflow 8-K filed, covering financials & Reg FD. Details TBD.

AI Summary

Heartflow, Inc. filed an 8-K on September 10, 2025, to report on its results of operations and financial condition, as well as a Regulation FD disclosure. The filing does not contain specific financial figures or details about the nature of the disclosure.

Why It Matters

This 8-K filing indicates that Heartflow, Inc. is providing updates on its financial performance and making disclosures under Regulation FD, which could impact investor understanding of the company's current standing.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial reporting and Regulation FD disclosure, without immediate indication of significant negative events.

Key Players & Entities

• Heartflow, Inc. (company) — Registrant
• September 10, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 331 E. Evelyn Avenue Mountain View, California 94041 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share HTFL The Nasdaq Sto
• $43.4 m — revenue is expected to be approximately $43.4 million, (ii) gross margin is expected to
• $46.5 million — penses are expected to be approximately $46.5 million. In addition, the Company will disclose
• $80.2 million — h equivalents balance was approximately $80.2 million as of June 30, 2025, which does not giv
• $333.0 million — roceeds to the Company of approximately $333.0 million upon the closing of its initial public
• $114.1 million — P and other parties thereto (comprising $114.1 million as of June 30, 2025) plus accrued inter

Filing Documents

• htfl-20250910.htm (8-K) — 28KB
• 0001464521-25-000009.txt ( ) — 145KB
• htfl-20250910.xsd (EX-101.SCH) — 2KB
• htfl-20250910_lab.xml (EX-101.LAB) — 22KB
• htfl-20250910_pre.xml (EX-101.PRE) — 13KB
• htfl-20250910_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. As previously disclosed, Heartflow, Inc. (the "Company") will participate at the Morgan Stanley 23 rd Annual Global Healthcare Conference today, September 10, 2025. In connection with meetings with investors at the conference, the Company has published an Investor Presentation on its website as described in Item 7.01 below (the "Investor Presentation"). In the Investor Presentation, the Company discloses the following preliminary unaudited results of operations for the three months ended June 30, 2025, which were initially disclosed as ranges in the Company's Registration Statement on Form S-1 (File No. 333-288733) filed with the U.S. Securities and Exchange Commission ("SEC") in connection with the Company's initial public offering completed on August 11, 2025: (i) revenue is expected to be approximately $43.4 million, (ii) gross margin is expected to be approximately 75.5%, and (iii) operating expenses are expected to be approximately $46.5 million. In addition, the Company will disclose that its cash and cash equivalents balance was approximately $80.2 million as of June 30, 2025, which does not give effect to the net proceeds to the Company of approximately $333.0 million upon the closing of its initial public offering or the repayment in full during the three months ended September 30, 2025 of all amounts outstanding under the Company's Credit Agreement and Guaranty with Hayfin Services LLP and other parties thereto (comprising $114.1 million as of June 30, 2025) plus accrued interest and related fees thereon. The financial information presented in this Item 2.02 is preliminary and unaudited based on the most recent information available to the Company's management as of the date hereof and does not reflect a comprehensive statement of the Company's financial results as of and for the three months ended June 30, 2025, which will be disclosed in the Company's Quarterly Report on Form 10-Q when filed

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. In connection with the Morgan Stanley 23 rd Annual Global Healthcare Conference, the Company is publishing the Investor Presentation on the Investors page of the Company's website at https://ir.heartflow.com. The information contained in Items 2.02 and 7.01 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HEARTFLOW, INC. Date: September 10, 2025 By: /s/ Vikram Verghese Vikram Verghese Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR